Efficacy and Safety of Radiotherapy Combined with PD-1 Inhibitors and Targeted Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective, Real-World Multicenter Study
The triple-combination of RT, PD-1 inhibitors, and targeted therapy demonstrates promising survival benefits and a manageable toxicity profile for uHCC. Baseline AFP, liver function, NLR level are key determinants of survival, supporting the individualized application of this multimodal approach.
Authors
- Ping Zheng (ORCID: https://orcid.org/0000-0002-3551-5536)
- Linbin Lu (ORCID: https://orcid.org/0000-0003-3779-3457)
- Yun-ying Nie
- Jialin Chen (ORCID: https://orcid.org/0000-0001-6294-876X)
- Xinying Guo
- Si-Miao Gao
- Wei-Xuan Xu
- Cheng Li
- Si-Ning Tang
- Xiong Chen
- Xiang-Long Chen
Institutions
- Fujian Medical University (CN)
- Mengchao Hepatobiliary Hospital (CN)
Publication Details
- Journal
- Journal of Hepatocellular Carcinoma
- Published
- 2026-02-01
- DOI
- https://doi.org/10.2147/jhc.s572797
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Fujian Province
- Fujian Medical University